Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELROSE: Osimertinib in EGFR Mutated NSCLC
NCT03865511Phase 2Active, not recruiting
- Sponsor
- CHU de Nantes
- Start
- Apr 2019
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by CHU de Nantes. Primary endpoint: Examination of the genetic profile at the point of disease progression in EGFRm+ patients receiving osimertinib as first-line EGFR TKI therapy compared to baseline. Started Apr 2019; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03865511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865511.